1. Pomerantz LLP is investigating possible securities fraud by Charming Medical. 2. Investors are advised to contact Pomerantz for claims related to MCTA. 3. SEC halted trading of MCTA due to suspected market manipulation. 4. Investigation involves officers and directors of Charming Medical. 5. Pomerantz specializes in securities fraud and corporate misconduct litigation.
FAQ
Why Very Bearish?
The halt in trading due to potential manipulation suggests severe trust issues which historically lead to significant price drops for affected companies.
How important is it?
The ongoing investigation and SEC actions pose immediate risks to MCTA's stability and investor confidence.
Why Short Term?
The immediate nature of the SEC’s actions and ongoing investigations create current uncertainty for MCTA’s investors.
Investigation Launched Over Claims Against Charming Medical Limited (NASDAQ: MCTA)
On December 30, 2025, Pomerantz LLP announced its investigation into potential securities fraud concerning Charming Medical Limited, identified by the stock symbol MCTA. This inquiry aims to protect the interests of investors and address allegations of unlawful business practices by the Company and its executives.
Details of the Investigation
Investors who have suffered losses related to Charming Medical Limited are advised to reach out to Danielle Peyton at newaction@pomlaw.com or by phone at 646-581-9980, ext. 7980. The investigation focuses on whether the Company’s officers and directors engaged in actions that could constitute securities fraud.
SEC Action and Trading Halt
On November 11, 2025, the U.S. Securities and Exchange Commission (SEC) intervened by halting all trading of MCTA securities. This decision was influenced by concerns over potential market manipulation. The SEC cited that there were recommendations circulating on social media from unknown parties encouraging investors to buy, hold, or sell shares of Charming Medical, with the intention of artificially inflating the stock price and trading volume.
As a result, trading of Charming Medical’s securities was suspended beginning November 12, 2025, raising significant implications for investors.
Pomerantz LLP: A Leader in Securities Litigation
Pomerantz LLP is recognized as a premier firm specializing in corporate, securities, and antitrust class action litigation. With offices in key locations including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, the firm has a long-standing history of advocating for victims of securities fraud and corporate misconduct.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the firm has a legacy of securing multimillion-dollar awards for class members, ensuring accountability in the financial markets.
Next Steps for Affected Investors
Investors affected by the trading halt or those with information pertinent to Pomerantz's investigation are encouraged to take action. Contacting Pomerantz LLP can provide you with essential guidance on the next steps, especially for those considering joining the class action.
For more information and updates, you can visit www.pomlaw.com.